BioCentury
ARTICLE | Clinical News

Archexin: Completed Phase II enrollment

October 3, 2011 7:00 AM UTC

Rexahn completed enrollment of about 35 patients with metastatic pancreatic cancer in a single-arm, open-label, U.S. and Indian Phase II trial evaluating 250 mg/m 2/day IV Archexin for the first 2 wee...